Thomas W. Hofmann
West Pharmaceutical Services Inc
United States of America
Mr. Thomas W. Hofmann, also known as Tom, served as Senior Vice President and Chief Financial Officer of Sunoco, Inc. from January 2002 to December 01, 2008 and from January 1998 to December 01, 2008 respectively. Mr. Hofmann served as Vice President of Sunoco, Inc. from July 1998 to January 2002 and its Comptroller from July 1995 to July 1998. Mr. Hofmann has 30 years of expertise in all areas of Finance including Tax, Accounting, Auditing, Treasury, Investor Relations, Budgeting and Performance Analysis and is well-versed in Corporate Governance. Mr. Hofmann has retired in December 2008. He started his career at Coopers & Lybrand (now, PricewaterhouseCoopers) in 1973 and joined Sunoco Inc. in 1977. He serves as Vice Chairman of Fox Chase Cancer Center. Mr. Hofmann has been Director of West Pharmaceutical Services, Inc. since October 16, 2007. He has been a Director of Northern Tier Energy LLC since May 2011. He has been Director at Northern Tier Energy GP LLC, the General Partner of Northern Tier Energy LP since June 2012. He serves as a Director of the Boys & Girls Clubs of Greater Philadelphia. He served as an Independent Director of CPP GP LLC - General Partner of Columbia Pipeline Partners LP since February 2015 until February 17, 2017. He served as Director at Sunoco Partners LLC from October 2001 to October 26, 2008. He served as Director of CareFusion 202, Inc. since April 15, 2004. He served on the board of directors of the general partner of Sunoco Logistics Partners, L.P. and VIASYS Healthcare Inc. He served as a Director of Penn Virginia Resource GP LLC and Penn Virginia Resource Partners LP from May 2009 to March 2014. Mr. Hofmann is a Member of the American Institute of Certified Public Accountants, the Pennsylvania Institute of Certified Public Accountants and the Financial Executives Institute. He holds a BS degree in Accounting from the University of Delaware and Master in Taxation from Villanova University.
company focused on developing and manufacturing difficult to develop, technology-driven specialty generics for the US markets. WES nurtures the entire product lifecycle-from the early stages of R&D through U.S. Food and Drug Administration (FDA) approval and manufacturing the approved product. WES’s professional team of scientists has expertise in developing multitude of dosage forms. WES develops majority of its products in-house in addition to partnering with other pharmaceutical companies to synergize development, manufacturing, and marketing capabilities.